Alivus Life Sciences · NSE: ALIVUS · BSE: 543322
Q1 FY27 results · Apr–Jun 2026
Alivus Life Sciences reported revenue from operations of ₹640.41 crore (up 6.4% from Q1 FY26) and net profit of ₹160.08 crore (up 31.7% from Q1 FY26) for Q1 FY27 (Apr–Jun 2026), on a standalone basis.
| Item | Q1 FY27 | Q1 FY26 | YoY | Q4 FY26 | QoQ |
|---|---|---|---|---|---|
| Revenue from operations | 640.41 | 601.85 | +6.4% | 689.12 | −7.1% |
| Other income | 22.40 | 8.98 | +149.3% | 22.78 | −1.7% |
| Total income | 662.82 | 610.83 | +8.5% | 711.89 | −6.9% |
| Profit before tax | 212.22 | 162.98 | +30.2% | 215.80 | −1.7% |
| Net profit for the period | 160.08 | 121.53 | +31.7% | 162.66 | −1.6% |
| EPS, basic (₹) | 13.04 | 9.91 | +31.6% | 13.23 | −1.4% |
| Net margin (%) | 25.0 | 20.2 | 23.6 |
Standalone
- Filed with BSE
- 30 Jul 2026, 19:14 IST
- Board meeting
- 30 Jul 2026
- Period
- 01 Apr 2026 to 30 Jun 2026
- Review status
- Unaudited
- Source
- XBRL filing on BSE